Nutraceuticals
Efficacy, Safety and Toxicity
2nd Edition
Published on 25. June 2021
Book
Hardback
1396 pages
978-0-12-821038-3 (ISBN)
Description
Nutraceuticals: Efficacy, Safety and Toxicity, Second Edition, brings together everything that is currently known about nutraceuticals and their potential toxic effects. The book introduces readers to nutraceuticals, herbal medicines, Ayurvedic medicines, prebiotics, probiotics, adaptogens, and their uses and specific applications. This essential reference discusses the mechanism of action for the judicious use of these nutraceuticals and the best tools for their evaluation before detailing the safety and toxicity of nutraceuticals and interactions with other therapeutic drugs. Finally, and crucially, regulatory aspects from around the world are covered.
Completely revised and updated, this updated edition provides toxicologists, pharmacologists, pharmaceutical scientists, and those interested in medicinal plants and natural products with a comprehensive overview of the most effective tools upon which to evaluate the safety and toxicity of nutraceuticals, prebiotics, probiotics and alternative medicines.
Completely revised and updated, this updated edition provides toxicologists, pharmacologists, pharmaceutical scientists, and those interested in medicinal plants and natural products with a comprehensive overview of the most effective tools upon which to evaluate the safety and toxicity of nutraceuticals, prebiotics, probiotics and alternative medicines.
More details
Edition
2nd edition
Language
English
Place of publication
San Diego
United States
Publishing group
Elsevier Science Publishing Co Inc
Target group
Professional and scholarly
Toxicologists, pharmacologists, pharmaceutical scientists, pharmacists, nutritionists, medicinal and natural product chemists
Product notice
sewn/stitched
Cloth over boards
Illustrations
128 illustrations (28 in full color); Illustrations
Dimensions
Height: 282 mm
Width: 218 mm
Thickness: 56 mm
Weight
2994 gr
ISBN-13
978-0-12-821038-3 (9780128210383)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
E-Book
01/2021
2nd Edition
Academic Press
€175.00
Available for download
Previous edition
Book
01/2016
Academic Press
€194.69
Article exhausted; check for reprint
Persons
Dr. Ramesh C. Gupta, Professor & Head of Toxicology Department at Murray State university, is engaged in experimental brain research in relation to Alzheimer's disease (AD) and pesticide toxicity. He has delivered lectures in Australia, Italy, Japan, Germany, France, Switzerland, Spain, Czech Republic, China, South Korea, and Sweden. He served the panels of NIH, CDC, NIOSH, and NAS. He has >350 publications to his credit, including seven major books with Elsevier: (1) Toxicology of Organophosphate and Carbamate Compounds, (2) Veterinary Toxicology: Basic and Clinical Principles, (3) Handbook of Toxicology of Chemical Warfare Agents, (4) Anticholinesterase Pesticides: Metabolism, Neurotoxicity, and Epidemiology, (5) Reproductive and Developmental Toxicology, (6) Biomarkers in Toxicology and (7) Neutraceuticals. He is recipient of Murray State University's distinguished researcher award of the year-2006. He is a diplomate of American Board of Toxicology, and fellow of American College of Toxicology, American College of Nutrition, and Academy of Toxicological Sciences. Mr. Rajiv Lall is the Founder and CEO of ProbioticSmart, LLC, a novel nutraceutical ingredients development company based on research and evidence-based science and Vets Plus, Inc., an international leader in the animal health industry. He graduated with two Masters degrees, the first in Botany from his native country of India, and the second in Pharmacognosy/Medicinal Chemistry from the University of Minnesota. His research focused on identifying, analyzing, and extracting natural ingredients from plants and plant tissue cultures that provide natural health and medicinal properties, as well as on enzymes in relation to cancer cells through animal cell cultures. Mr. Lall started his career in the human health food industry with an emphasis on probiotics. His relentless drive continues to champion both human and animal health through scientific research and the development of nutritional products and pharmaceuticals, and through these efforts he has obtained various patents and developed several hundred products. His company, Vets Plus, Inc. is a research and science-based product development company with a strong quality and manufacturing platform to support partners in Europe and around the world. Recent awards include the Pet Age Icon Award (2015), NASC Visibility Award (2015), and Menomonie Area Chamber of Commerce Business of the Year Award (2015). Vets Plus Inc. was also nominated for Wisconsin Manufacturer of the Year in 2015. In support of the animal health industry, Mr. Lall is now Founder and CEO of Noble Pharma, LLC, a pharmaceutical company in Menomonie, Wisconsin. Mr. Lall and his wife Swati are involved in philanthropic efforts and through that they have developed the Raj and Swati Lall Microbiology Laboratory at the University of Wisconsin-Stout in support of future scientists and business leaders and the community in Menomonie, Wisconsin. Dr. Ajay Srivastava is Chief Scientific Officer at Vets Plus Inc. and serves as an adjunct Faculty member at University of Wisconsin-Stout, Menomonie, US. He is specialized in preclinical and clinical product development and nutraceutical research. After receiving his BS in Biological Sciences, Dr. Srivastava earned his DVM from the School of Veterinary Medicine at GB Pant University of Agriculture and Technology, India, before pursuing his MS in Pharmacology. He completed his PhD in Neuropharmacology from All India Institute of Medical Sciences, New Delhi. After his post-doctoral training in preclinical drug development in neurological disorders, Dr. Srivastava became Senior Research Scientist of the Anticonvulsant Drug Development Program at the University of Utah, where he developed a novel animal model of pharmacoresistant epilepsy to screen potential antiepileptic drugs. He is one of the pioneer researchers who discovered the role of nutraceuticals resveratrol and melatonin in epilepsy. Dr. Srivastava has chaired various scientific sessions in AVMA and WVC meetings and has published several research articles in peer reviewed journals. He has contributed chapters in textbooks on epilepsy, toxicology and nutraceuticals.
Content
Section I. Applications of nutraceuticals in common diseases and disorders
1. Nutraceuticals in central nervous system diseases: potential mechanisms of neuroprotection
2. Prevention of neurodegenerative disorders by nutraceuticals
3. Cognitive effects of nutraceuticals
4. Nutraceuticals in anxiety and stress
5. Countering cardiovascular diseases with nutraceuticals
6. Nutraceuticals for diabetes and glucose balance
7. Role of nutraceuticals in respiratory and allied diseases
8. Nutraceuticals in hepatic diseases
9. Nutraceuticals in renal diseases
10. Nutraceuticals in gastrointestinal disorders
11. Nutraceuticals in reproductive and developmental disorders
12. Nutraceuticals in ophthalmic diseases
13. Nutraceuticals in dermal diseases
14. Nutraceuticals in arthritis
15. Nutraceuticals in sports activities and fatigue
16. Role of nutraceuticals as adaptogens
17. Nutraceuticals for weight loss
18. Nutraceuticals in cancer prevention
19. Application of "nano? nutraceuticals in medicine
Section II. Models and mechanisms in evaluation of nutraceuticals
20. The biology of nutrients: genetic and molecular principles
21. Genomic and proteomic mechanisms and models in toxicity and safety evaluation of nutraceuticals
22. Transcriptomic profiling for safety and toxicity evaluation of
nutraceuticals
23. Target identification and polypharmacology of nutraceuticals
24. Systems pharmacology investigation of mechanism of action of nutraceuticals
25. Noninvasive in vivo optical imaging models for safety and toxicity testing
26. Flow cytometry and light-scattering techniques in evaluation of nutraceuticals
27. Zebrafish as a model system to evaluate the safety and toxicity of nutraceuticals
28. Caenorhabditis elegans: an elegant model organism for evaluating the neuroprotective and neurotherapeutic potential of nutraceuticals
29. Alternative in vitro models for safety and toxicity evaluation of nutraceuticals
30. Mitochondria as a target for safety and toxicity evaluation of nutraceuticals
31. Oxidative stress and excitotoxicity: antioxidants from nutraceuticals
Section III. Common nutraceuticals
32. Caffeine: an evaluation of the safety database
33. Biological activities and potential nanotechnological delivery of resveratrol
34. Melatonin: a safe nutraceutical and clinical agent
35. Standardized turmeric and curcumin
36. Curcuminoid-metal complexes for oxidative stress
37. Fenugreek: multiple health benefits
38. Cannabis sativa: an overview
39. Cannabidiol safety
40. St John's wort (Hypericum perforatum L)
41. Green tea
42. Green coffee beans
43. Quercetin
44. German chamomile
45. Isoflavones: toxicological aspects and efficacy
46. Propolis
47. Bee products as nutraceuticals to nutraceuticals for bees
48. Ginkgo biloba
49. Chinese ginseng
50. Ashwagandha: multiple health benefits
51. Astaxanthin: health benefits and toxicity
52. Thymoquinone
53. Glucosinolates
54. Organosulfur compounds as nutraceuticals
55. Arginine and citrulline as nutraceuticals: efficacy and safety in diseases
56. Neem Extract
57. Spirulina
58. Garcinia cambogia
59. Vitamin E TPGS and its applications in nutraceuticals
60. Role of transferrin: an iron-binding protein in health and diseases
61. Glutamine supplementation: hope, hype, or stay tuned?
62. What to do with placenta after birth: is it a waste?
63. Chitin, chitosan, and their derivatives
Section IV. Prebiotics and probiotics
64. Prebiotics: safety and toxicity considerations
65. Probiotics: safety and toxicity considerations
66. Synbiotics: safety and toxicity considerations
Section V. Nutraceuticals in veterinary medicine
67. Nutraceuticals in animal health and diseases
Section VI. Toxicity and toxic interactions
68. Toxic contamination of nutraceuticals and food ingredients
69. Nutraceuticals and adverse outcome pathways
70. Interactions between nutraceuticals/nutrients and nutrients and therapeutic drugs
71. Genotoxicity evaluation of nutraceuticals
Section VII. Regulatory aspects
72. The regulatory framework for nutraceuticals: North America
73. Evaluation and regulation of food supplements: European perspective
74. Regulatory guidelines for nutraceuticals in India: an overview
75. Regulatory aspects of nutraceuticals: Chinese perspective
76. Uses and regulation of nutraceuticals: Australia and New Zealand
77. Regulatory aspects of nutraceuticals: Japanese perspective
78. Nutraceuticals: the Turkish perspective
1. Nutraceuticals in central nervous system diseases: potential mechanisms of neuroprotection
2. Prevention of neurodegenerative disorders by nutraceuticals
3. Cognitive effects of nutraceuticals
4. Nutraceuticals in anxiety and stress
5. Countering cardiovascular diseases with nutraceuticals
6. Nutraceuticals for diabetes and glucose balance
7. Role of nutraceuticals in respiratory and allied diseases
8. Nutraceuticals in hepatic diseases
9. Nutraceuticals in renal diseases
10. Nutraceuticals in gastrointestinal disorders
11. Nutraceuticals in reproductive and developmental disorders
12. Nutraceuticals in ophthalmic diseases
13. Nutraceuticals in dermal diseases
14. Nutraceuticals in arthritis
15. Nutraceuticals in sports activities and fatigue
16. Role of nutraceuticals as adaptogens
17. Nutraceuticals for weight loss
18. Nutraceuticals in cancer prevention
19. Application of "nano? nutraceuticals in medicine
Section II. Models and mechanisms in evaluation of nutraceuticals
20. The biology of nutrients: genetic and molecular principles
21. Genomic and proteomic mechanisms and models in toxicity and safety evaluation of nutraceuticals
22. Transcriptomic profiling for safety and toxicity evaluation of
nutraceuticals
23. Target identification and polypharmacology of nutraceuticals
24. Systems pharmacology investigation of mechanism of action of nutraceuticals
25. Noninvasive in vivo optical imaging models for safety and toxicity testing
26. Flow cytometry and light-scattering techniques in evaluation of nutraceuticals
27. Zebrafish as a model system to evaluate the safety and toxicity of nutraceuticals
28. Caenorhabditis elegans: an elegant model organism for evaluating the neuroprotective and neurotherapeutic potential of nutraceuticals
29. Alternative in vitro models for safety and toxicity evaluation of nutraceuticals
30. Mitochondria as a target for safety and toxicity evaluation of nutraceuticals
31. Oxidative stress and excitotoxicity: antioxidants from nutraceuticals
Section III. Common nutraceuticals
32. Caffeine: an evaluation of the safety database
33. Biological activities and potential nanotechnological delivery of resveratrol
34. Melatonin: a safe nutraceutical and clinical agent
35. Standardized turmeric and curcumin
36. Curcuminoid-metal complexes for oxidative stress
37. Fenugreek: multiple health benefits
38. Cannabis sativa: an overview
39. Cannabidiol safety
40. St John's wort (Hypericum perforatum L)
41. Green tea
42. Green coffee beans
43. Quercetin
44. German chamomile
45. Isoflavones: toxicological aspects and efficacy
46. Propolis
47. Bee products as nutraceuticals to nutraceuticals for bees
48. Ginkgo biloba
49. Chinese ginseng
50. Ashwagandha: multiple health benefits
51. Astaxanthin: health benefits and toxicity
52. Thymoquinone
53. Glucosinolates
54. Organosulfur compounds as nutraceuticals
55. Arginine and citrulline as nutraceuticals: efficacy and safety in diseases
56. Neem Extract
57. Spirulina
58. Garcinia cambogia
59. Vitamin E TPGS and its applications in nutraceuticals
60. Role of transferrin: an iron-binding protein in health and diseases
61. Glutamine supplementation: hope, hype, or stay tuned?
62. What to do with placenta after birth: is it a waste?
63. Chitin, chitosan, and their derivatives
Section IV. Prebiotics and probiotics
64. Prebiotics: safety and toxicity considerations
65. Probiotics: safety and toxicity considerations
66. Synbiotics: safety and toxicity considerations
Section V. Nutraceuticals in veterinary medicine
67. Nutraceuticals in animal health and diseases
Section VI. Toxicity and toxic interactions
68. Toxic contamination of nutraceuticals and food ingredients
69. Nutraceuticals and adverse outcome pathways
70. Interactions between nutraceuticals/nutrients and nutrients and therapeutic drugs
71. Genotoxicity evaluation of nutraceuticals
Section VII. Regulatory aspects
72. The regulatory framework for nutraceuticals: North America
73. Evaluation and regulation of food supplements: European perspective
74. Regulatory guidelines for nutraceuticals in India: an overview
75. Regulatory aspects of nutraceuticals: Chinese perspective
76. Uses and regulation of nutraceuticals: Australia and New Zealand
77. Regulatory aspects of nutraceuticals: Japanese perspective
78. Nutraceuticals: the Turkish perspective